-
EP3536320
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3536320
| EP3536320 - APPLICATION OF HEDGEHOG PATHWAY INHIBITOR FOR TREATMENT OF FIBROTIC DISEASES [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 06.05.2022 Database last updated on 02.09.2024 | |
| Former | Examination is in progress Status updated on 03.09.2021 | ||
| Former | Request for examination was made Status updated on 09.08.2019 | ||
| Former | The international publication has been made Status updated on 11.05.2018 | Most recent event Tooltip | 06.05.2022 | Application deemed to be withdrawn | published on 08.06.2022 [2022/23] | Applicant(s) | For all designated states Impact Therapeutics (Shanghai), Inc Room 603, No. 3 Building 111 Xiangke Road Pilot Free Trade Zone Shanghai 201210 / CN | [2021/52] |
| Former [2021/51] | For all designated states Impact Therapeutics, Inc. Room 306, No.1 Building 898 Halei Road Shanghai 201210 / CN | ||
| Former [2019/37] | For all designated states Impact Therapeutics, Inc Room 603, No. 3 Building 111 Xiangke Road China (Shanghai) Pilot Free Trade Zone Shanghai 201210 / CN | Inventor(s) | 01 /
CAI, Sui Xiong Room 1102, No. 37, Lane 828 Chenhui Road Pudong New Area Shanghai 201203 / CN | 02 /
TIAN, Ye Edward Room 501 No. 36 Lane 2222 Hongmei Garden Hongqiao Road Changning District Shanghai 200336 / CN | [2019/37] | Representative(s) | van Dam, Vincent Octrooibureau Vriesendorp & Gaade B.V. Koninginnegracht 19 2514 AB Den Haag / NL | [2019/37] | Application number, filing date | 17867700.1 | 02.11.2017 | [2019/37] | WO2017CN109021 | Priority number, date | CN201610972163 | 04.11.2016 Original published format: CN201610972163 | [2019/37] | Filing language | ZH | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2018082587 | Date: | 11.05.2018 | Language: | ZH | [2018/19] | Type: | A1 Application with search report | No.: | EP3536320 | Date: | 11.09.2019 | Language: | EN | [2019/37] | Search report(s) | International search report - published on: | CN | 11.05.2018 | (Supplementary) European search report - dispatched on: | EP | 30.06.2020 | Classification | IPC: | A61K31/496, A61P11/00, A61P1/16, A61P37/06, A61P9/00, A61P13/12, A61P17/00 | [2020/31] | CPC: |
A61P1/16 (EP,US);
A61K31/496 (EP,US);
A61P11/00 (EP,US);
A61P13/12 (EP);
A61P17/00 (EP);
A61P37/06 (EP,US);
A61P9/00 (EP)
(-)
|
| Former IPC [2019/37] | A61K31/496, A61P11/00, A61P37/06 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/37] | Title | German: | ANWENDUNG EINES HEDGEHOG-SIGNALWEG-INHIBITORS ZUR BEHANDLUNG VON FIBROTISCHEN ERKRANKUNGEN | [2019/37] | English: | APPLICATION OF HEDGEHOG PATHWAY INHIBITOR FOR TREATMENT OF FIBROTIC DISEASES | [2019/37] | French: | APPLICATION D'UN INHIBITEUR DE LA VOIE HEDGEHOG SERVANT AU TRAITEMENT DE MALADIES FIBROTIQUES | [2019/37] | Entry into regional phase | 29.05.2019 | Translation filed | 29.05.2019 | National basic fee paid | 29.05.2019 | Search fee paid | 29.05.2019 | Designation fee(s) paid | 29.05.2019 | Examination fee paid | Examination procedure | 29.05.2019 | Examination requested [2019/37] | 18.01.2021 | Amendment by applicant (claims and/or description) | 02.09.2021 | Despatch of a communication from the examining division (Time limit: M04) | 13.01.2022 | Application deemed to be withdrawn, date of legal effect [2022/23] | 02.02.2022 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2022/23] | Fees paid | Renewal fee | 01.11.2019 | Renewal fee patent year 03 | 04.11.2020 | Renewal fee patent year 04 | 04.11.2021 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]WO2009030952 (ASTRAZENECA AB [SE], et al) [Y] 1-15 * page 3, paragraph l - page 4, paragraph 1 * * page 53; compound 35 * * page 54; compound 38 * * page 55; compound 42 ** claims 7, 8 *; | [Y]WO2011088404 (INFINITY PHARMACEUTICALS INC [US], et al) [Y] 1-15 * page 6, lines 13-15 * * page 58, line 28 - page 59, line 1 * * claims 1, 4-9 *; | [YD]WO2014012511 (IMPACT THERAPEUTICS INC [CN]) [YD] 1-15 * page 3, paragraph [0006] * * page 93; example 171 * * pages 113-114; table 3 * * page 127, lines 23-24 * * claims 1, 6, 8, 9, 14 *; | [Y] - M. NOUREDDIN ET AL, "Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis", ALIMENTARY PHARMACOLOGY & THERAPEUTICS., GB, (20160408), vol. 43, no. 11, doi:10.1111/apt.13620, ISSN 0269-2813, pages 1109 - 1123, XP055322160 [Y] 1-15 * page 1113; figure 3 * * page 1118, column 2, paragraph 1 * DOI: http://dx.doi.org/10.1111/apt.13620 |